Stock Financial Ratios


NVLN / NOVELION THERAPEUTICS INC. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price4.52
Volume87,400.00
Market Cap ($M)79.55
Enterprise Value ($M)-3.93
Book Value ($M)135.79
Book Value / Share12.03
Price / Book0.58
NCAV ($M)361.98
NCAV / Share32.08
Price / NCAV0.25
Income Statement (mra) ($M)
Revenue13.57
EBITDA-36.71
Net Income-52.87
Balance Sheet (mrq) ($M)
Cash & Equivalents70.50
Cash / Share6.25
Assets392.61
Liabilities307.00
Quick Ratio0.77
Current Ratio1.40
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.39
Return on Assets (ROA)-0.11
Return on Equity (ROE)-0.39
Identifiers and Descriptors
CUSIP6700K2029
Central Index Key (CIK)827809
Industry Groups
SIC 2834 - Pharmaceutical Preparations
Other Related CUSIPS
67001K202
67001K952
67001K103
67001K902
Share Statistics
Common Shares Outstanding (M)18.65
Scoring Models
Piotroski F Score5.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Inventory Work In Progress Per Share0.00
Property Plant And Equipment Net Per Share0.31
Long Term Debt Per Share0.00
Treasury Stock Per Share0.00
Assets Current Per Share10.21
Assets Other Non Current Per Share0.20
Debt Per Share0.00
Liabilities Per Share27.21
Deferred Income Tax Liabilities Per Share0.00
Cash Per Share6.25
Intangibles Per Share20.52
Retained Earnings Per Share-61.10
Goodwill Per Share0.00
Accumulated Depreciation And Depletion Per Share0.00
Equity Per Share3.39
Accounts Receivable Per Share1.29
Minority Interest Per Share0.00
Current Portion Of Long Term Debt Per Share0.00
Property Plant And Equipment Gross Per Share0.00
Liabilities Other Non Current Per Share0.05
Property Plant And Equipment Per Share0.31
Assets Per Share34.79
Inventory Raw Materials Per Share0.00
Assets Other Current Per Share0.00
Liabilities Current Per Share5.02
Inventory Finished Goods Per Share0.00
Accounts Payable Per Share0.00
Inventory Per Share1.39
Assets Non Current Per Share0.00
Preferred Stock Value Outstanding Per Share0.00
Cash And Equivalents Per Share6.25
Additional Paid In Capital Per Share6.39
Liabilities And Stock Equity Per Share36.19

Related News Stories

BRIEF-Novelion Therapeutics provides update on agreement between Aegerion Pharma and U.S. Department of Justice

15h reuters
* Novelion Therapeutics - ‍district judge William Young rejected Aegerion Pharmaceuticals’ amended criminal plea agreement which was negotiated with U.S. DOJ (8-0)

U.S. judge rejects plea deal with Novelion's Aegerion

2017-11-20 reuters
BOSTON (Reuters) - A U.S. judge on Monday rejected a plea deal that was part of Aegerion Pharmaceuticals Inc’s recent agreement to pay $40.1 million to resolve U.S. probes into its marketing of a cholesterol drug, saying it was “not in the public interest.” (8-0)

Astellas faces U.S. probe over patient assistance charity support

2017-11-15 reuters
BOSTON (Reuters) - Astellas Pharma Inc has become the latest company to reveal it has become the subject of a U.S. probe into drugmakers’ financial support of charities offering assistance to Medicare patients seeking help to cover out-of-pocket drug costs. (259-0)

RPT-U.S. judge says he may reject plea deal with Novelion's Aegerion

2017-10-18 reuters
BOSTON, Oct 18 (Reuters) - A U.S. judge on Wednesday said he may reject a plea agreement that was part of Aegerion Pharmaceuticals Inc’s $35 million settlement with the U.S. Justice Department to resolve claims related to its marketing of an expensive cholesterol drug. (8-0)

U.S. judge says he may reject plea deal with Novelion's Aegerion

2017-10-18 reuters
BOSTON, Oct 18 (Reuters) - A U.S. judge on Wednesday said he may reject a plea agreement that was part of Aegerion Pharmaceuticals Inc’s $35 million settlement with the U.S. Justice Department to resolve claims related to its marketing of an expensive cholesterol drug. (8-0)

CUSIP: 6700K2029